AR120082A1 - Inhibidores de fosfatasa shp-2 y métodos para fabricarlos y usarlos - Google Patents
Inhibidores de fosfatasa shp-2 y métodos para fabricarlos y usarlosInfo
- Publication number
- AR120082A1 AR120082A1 ARP200102641A ARP200102641A AR120082A1 AR 120082 A1 AR120082 A1 AR 120082A1 AR P200102641 A ARP200102641 A AR P200102641A AR P200102641 A ARP200102641 A AR P200102641A AR 120082 A1 AR120082 A1 AR 120082A1
- Authority
- AR
- Argentina
- Prior art keywords
- acid
- shp
- making
- methods
- solvate
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/13—Crystalline forms, e.g. polymorphs
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Reivindicación 1: Una forma sólida del Compuesto de fórmula (2) o un solvato de este. Reivindicación 4: La forma sólida de la reivindicación 3, caracterizada por un patrón de difracción de polvos de rayos X con al menos dos picos característicos, en grados 2q, cada uno seleccionado del grupo que consiste en aproximadamente 24,6, aproximadamente 19,9, y aproximadamente 16,0 2q. Reivindicación 8: Un compuesto de la fórmula (1), o un solvato de este; donde, m es 1 a 9; n es 1 a 3; y X se selecciona del grupo que consiste en ácido clorhídrico, ácido bromhidrato, ácido sulfúrico, ácido metanosulfónico, ácido fosfórico, ácido p-toluenosulfónico, ácido bencensulfónico, ácido oxálico, ácido L-aspártico, ácido maleico, ácido malónico, ácido L-tartárico, ácido fumárico, ácido cítrico, ácido succínico y ácido glutárico.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962904986P | 2019-09-24 | 2019-09-24 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR120082A1 true AR120082A1 (es) | 2022-02-02 |
Family
ID=72752547
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP200102641A AR120082A1 (es) | 2019-09-24 | 2020-09-23 | Inhibidores de fosfatasa shp-2 y métodos para fabricarlos y usarlos |
Country Status (13)
Country | Link |
---|---|
US (2) | US11890281B2 (es) |
EP (1) | EP4034539A1 (es) |
JP (1) | JP2022548792A (es) |
KR (1) | KR20220066923A (es) |
CN (1) | CN114450287A (es) |
AR (1) | AR120082A1 (es) |
AU (1) | AU2020354475A1 (es) |
BR (1) | BR112022005349A2 (es) |
CA (1) | CA3154862A1 (es) |
IL (1) | IL291285A (es) |
MX (1) | MX2022003454A (es) |
TW (1) | TW202126660A (es) |
WO (1) | WO2021061706A1 (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
WO2021257736A1 (en) | 2020-06-18 | 2021-12-23 | Revolution Medicines, Inc. | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors |
IL301062A (en) | 2020-09-03 | 2023-05-01 | Revolution Medicines Inc | Use of SOS1 inhibitors to treat malignancies with SHP2 mutations |
PE20231207A1 (es) | 2020-09-15 | 2023-08-17 | Revolution Medicines Inc | Derivados indolicos como inhibidores de ras en el tratamiento del cancer |
WO2022235870A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors for the treatment of cancer |
CN117500811A (zh) | 2021-05-05 | 2024-02-02 | 锐新医药公司 | 共价ras抑制剂及其用途 |
WO2022235864A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Ras inhibitors |
CN115368373A (zh) | 2021-05-21 | 2022-11-22 | 石药集团中奇制药技术(石家庄)有限公司 | 螺环类化合物及其用途 |
TW202317100A (zh) | 2021-06-23 | 2023-05-01 | 瑞士商諾華公司 | 包含kras g12c抑制劑的藥物組合及其用於治療癌症之用途 |
WO2023031781A1 (en) | 2021-09-01 | 2023-03-09 | Novartis Ag | Pharmaceutical combinations comprising a tead inhibitor and uses thereof for the treatment of cancers |
WO2023051717A1 (zh) * | 2021-09-29 | 2023-04-06 | 微境生物医药科技(上海)有限公司 | 作为shp2抑制剂的稠环化合物 |
AR127308A1 (es) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | Inhibidores ras |
WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
WO2023220703A1 (en) * | 2022-05-12 | 2023-11-16 | Genentech, Inc. | Methods and compositions comprising a shp2 inhibitor and a pd-l1 binding antagonist |
WO2023240263A1 (en) | 2022-06-10 | 2023-12-14 | Revolution Medicines, Inc. | Macrocyclic ras inhibitors |
Family Cites Families (57)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5466823A (en) | 1993-11-30 | 1995-11-14 | G.D. Searle & Co. | Substituted pyrazolyl benzenesulfonamides |
RU2379303C2 (ru) | 2003-04-24 | 2010-01-20 | Инсайт Корпорейшн | Производные азаспироалканов в качестве ингибиторов металлопротеаз |
US20060135571A1 (en) | 2003-06-13 | 2006-06-22 | Jaquith James B | Imidazo(2,1-b)-1,3,4-thiadiazole sulfoxides and sulfones |
US9174969B2 (en) | 2008-07-21 | 2015-11-03 | University Of South Florida | Indoline scaffold SHP-2 inhibitors and cancer treatment method |
WO2010012345A1 (en) | 2008-07-29 | 2010-02-04 | Merck Patent Gmbh | Imidazothiadiazoles derivatives |
CN102325780B (zh) | 2009-02-25 | 2014-12-03 | 乌菲尔有限公司 | 6-苯基-2-[((哌啶-4-基-甲基)-哌嗪-1-基)或者((哌嗪-1-基-甲基)-哌啶-1-基)]-咪唑-[2,1-b][1,3,4]噻二唑衍生物及其应用 |
WO2010121212A2 (en) | 2009-04-17 | 2010-10-21 | H. Lee Moffit Cancer Center And Research Institute, Inc. | Indoline scaffold shp-2 inhibitors and method of treating cancer |
US20110256331A1 (en) | 2010-04-14 | 2011-10-20 | Dak Americas Llc | Ultra-high iv polyester for extrusion blow molding and method for its production |
CN103570622B (zh) | 2012-09-07 | 2015-02-04 | 北京京卫燕康药物研究所有限公司 | 塞来昔布的制备方法 |
JO3517B1 (ar) | 2014-01-17 | 2020-07-05 | Novartis Ag | ان-ازاسبيرو الكان حلقي كبديل مركبات اريل-ان مغايرة وتركيبات لتثبيط نشاط shp2 |
CN105899493B (zh) * | 2014-01-17 | 2019-03-29 | 诺华股份有限公司 | 用于抑制shp2活性的1-(三嗪-3-基/哒嗪-3-基)-哌(-嗪)啶衍生物及其组合物 |
US10093646B2 (en) | 2014-01-17 | 2018-10-09 | Novartis Ag | 1-pyridazin-/triazin-3-yl-piper(-azine)/idine/pyrolidine derivatives and compositions thereof for inhibiting the activity of SHP2 |
ES2741746T3 (es) | 2015-06-19 | 2020-02-12 | Novartis Ag | Compuestos y composiciones para inhibir la actividad de SHP2 |
EP3310774B1 (en) | 2015-06-19 | 2020-04-29 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
EP3310771B1 (en) | 2015-06-19 | 2020-07-22 | Novartis AG | Compounds and compositions for inhibiting the activity of shp2 |
WO2017156397A1 (en) | 2016-03-11 | 2017-09-14 | Board Of Regents, The University Of Texas Sysytem | Heterocyclic inhibitors of ptpn11 |
CN107286150B (zh) | 2016-04-11 | 2020-07-07 | 中国科学院上海有机化学研究所 | N-杂环类化合物、其中间体、制备方法、药物组合物和应用 |
CN109475531B (zh) | 2016-05-31 | 2021-08-17 | 得克萨斯州立大学董事会 | Ptpn11的杂环抑制剂 |
KR20230109185A (ko) | 2016-06-07 | 2023-07-19 | 자코바이오 파마슈티칼스 컴퍼니 리미티드 | Shp2 억제제로서 유용한 신규한 헤테로환형 유도체 |
WO2017216706A1 (en) | 2016-06-14 | 2017-12-21 | Novartis Ag | Compounds and compositions for inhibiting the activity of shp2 |
CN109983001B (zh) | 2016-07-12 | 2023-04-04 | 锐新医药公司 | 作为变构shp2抑制剂的2,5-双取代型3-甲基吡嗪及2,5,6-三取代型3-甲基吡嗪 |
WO2018057884A1 (en) | 2016-09-22 | 2018-03-29 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
TW201819386A (zh) | 2016-10-24 | 2018-06-01 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
IL296456A (en) | 2017-01-23 | 2022-11-01 | Revolution Medicines Inc | Bicyclics as allosteric shp2 inhibitors |
BR112019014527A2 (pt) | 2017-01-23 | 2020-02-27 | Revolution Medicines, Inc. | Compostos de piridina como inibidores de shp2 alostéricos |
JP6878615B2 (ja) | 2017-03-23 | 2021-05-26 | ジャコバイオ ファーマスーティカルズ カンパニー リミテッドJacobio Pharmaceuticals Co., Ltd. | Shp2阻害剤として有用な新規な複素環式誘導体 |
EP3630770A1 (en) | 2017-05-26 | 2020-04-08 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine derivatives as shp2 phosphatase inhibitors |
AU2018328273A1 (en) | 2017-09-07 | 2020-03-12 | Revolution Medicines, Inc. | SHP2 inhibitor compositions and methods for treating cancer |
US10435389B2 (en) | 2017-09-11 | 2019-10-08 | Krouzon Pharmaccuticals, Inc. | Octahydrocyclopenta[c]pyrrole allosteric inhibitors of SHP2 |
US11701354B2 (en) | 2017-09-29 | 2023-07-18 | D. E. Shaw Research, Llc | Pyrazolo[3,4-b]pyrazine derivatives as SHP2 phosphatase inhibitors |
AU2018347516A1 (en) | 2017-10-12 | 2020-05-07 | Revolution Medicines, Inc. | Pyridine, pyrazine, and triazine compounds as allosteric SHP2 inhibitors |
TWI697490B (zh) | 2017-12-06 | 2020-07-01 | 大陸商北京加科思新藥研發有限公司 | 用於作為shp2抑制劑之新穎雜環衍生物 |
SG11202004090YA (en) | 2017-12-15 | 2020-05-28 | Revolution Medicines Inc | Polycyclic compounds as allosteric shp2 inhibitors |
SG11202007740TA (en) | 2018-02-13 | 2020-09-29 | Shanghai Blueray Biopharma Co Ltd | Pyrimidine-fused cyclic compound, preparation method therefor and application thereof |
EP3755699A1 (en) | 2018-02-21 | 2020-12-30 | Relay Therapeutics, Inc. | Shp2 phosphatase inhibitors and methods of use thereof |
CA3092011A1 (en) | 2018-03-02 | 2019-09-06 | Otsuka Pharmaceutical Co., Ltd. | Pharmaceutical compounds |
EP3768680A1 (en) | 2018-03-21 | 2021-01-27 | Relay Therapeutics, Inc. | Pyrazolo[3,4-b]pyrazine shp2 phosphatase inhibitors and methods of use thereof |
AU2019239658A1 (en) | 2018-03-21 | 2020-11-12 | Suzhou Puhe BioPharma Co., Ltd. | SHP2 inhibitors and uses thereof |
TW202003471A (zh) | 2018-03-21 | 2020-01-16 | 美商傳達治療有限公司 | Shp2磷酸酶抑制劑及其使用方法 |
SG11202009793TA (en) | 2018-04-10 | 2020-10-29 | Revolution Medicines Inc | Shp2 inhibitor compositions, methods for treating cancer and methods for identifying a subject with shp2 mutations |
SG11202010822SA (en) | 2018-05-02 | 2020-11-27 | Navire Pharma Inc | Substituted heterocyclic inhibitors of ptpn11 |
CN112409334B (zh) | 2018-05-09 | 2022-12-02 | 北京加科思新药研发有限公司 | 可用作shp2抑制剂的杂环衍生物 |
WO2019233810A1 (en) | 2018-06-04 | 2019-12-12 | Bayer Aktiengesellschaft | Inhibitors of shp2 |
US20220363693A1 (en) | 2018-07-24 | 2022-11-17 | Taiho Pharmaceutical Co., Ltd. | Heterobicyclic compounds for inhibiting the activity of shp2 |
SG11202100199UA (en) | 2018-08-10 | 2021-02-25 | Navire Pharma Inc | 6-(4-amino-3-methyl-2-oxa-8-azaspiro[4.5]decan-8-yl)-3-(2,3-dichlorophenyl)-2-methylpyrimidin-4(3h)-one derivatives and related compounds as ptpn11 (shp2) inhibitors for treating cancer |
CA3113234A1 (en) | 2018-09-18 | 2020-03-26 | Nikang Therapeutics, Inc. | Tri-substituted heteroaryl derivatives as src homology-2 phosphatase inhibitors |
US20210393623A1 (en) | 2018-09-26 | 2021-12-23 | Jacobio Pharmaceuticals Co., Ltd. | Novel Heterocyclic Derivatives Useful as SHP2 Inhibitors |
EP4282416A3 (en) | 2018-09-29 | 2024-03-06 | Novartis AG | Process of manufacture of a compound for inhibiting the activity of shp2 |
AU2019346118B2 (en) | 2018-09-29 | 2024-05-16 | Novartis Ag | Manufacture of compounds and compositions for inhibiting the activity of SHP2 |
WO2020072656A1 (en) | 2018-10-03 | 2020-04-09 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
EP3863636A1 (en) | 2018-10-08 | 2021-08-18 | Revolution Medicines, Inc. | Shp2 inhibitor compositions for use in treating cancer |
CN111295384B (zh) | 2018-10-10 | 2022-08-12 | 江苏豪森药业集团有限公司 | 双环类衍生物抑制剂、其制备方法和应用 |
TW202028183A (zh) | 2018-10-10 | 2020-08-01 | 大陸商江蘇豪森藥業集團有限公司 | 含氮雜芳類衍生物調節劑、其製備方法和應用 |
CA3116561C (en) | 2018-10-17 | 2023-09-12 | Array Biopharma Inc. | Protein tyrosine phosphatase inhibitors |
CN117143079A (zh) | 2018-11-06 | 2023-12-01 | 上海奕拓医药科技有限责任公司 | 一种螺芳环化合物及其应用 |
US20220127271A1 (en) | 2018-11-07 | 2022-04-28 | Shanghai Ringene Biopharma Co., Ltd. | Nitrogen-containing fused heterocyclic shp2 inhibitor compound, preparation method, and use |
CN111153899B (zh) | 2018-11-08 | 2023-12-01 | 四川科伦博泰生物医药股份有限公司 | 一种取代吡啶化合物、其制备方法和用途 |
-
2020
- 2020-09-23 US US17/029,376 patent/US11890281B2/en active Active
- 2020-09-23 TW TW109132962A patent/TW202126660A/zh unknown
- 2020-09-23 AU AU2020354475A patent/AU2020354475A1/en active Pending
- 2020-09-23 CN CN202080067472.2A patent/CN114450287A/zh active Pending
- 2020-09-23 WO PCT/US2020/052118 patent/WO2021061706A1/en unknown
- 2020-09-23 MX MX2022003454A patent/MX2022003454A/es unknown
- 2020-09-23 AR ARP200102641A patent/AR120082A1/es unknown
- 2020-09-23 EP EP20786408.3A patent/EP4034539A1/en active Pending
- 2020-09-23 JP JP2022518731A patent/JP2022548792A/ja active Pending
- 2020-09-23 KR KR1020227012907A patent/KR20220066923A/ko unknown
- 2020-09-23 BR BR112022005349A patent/BR112022005349A2/pt unknown
- 2020-09-23 CA CA3154862A patent/CA3154862A1/en active Pending
-
2022
- 2022-03-10 IL IL291285A patent/IL291285A/en unknown
-
2023
- 2023-12-19 US US18/545,478 patent/US20240122925A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114450287A (zh) | 2022-05-06 |
JP2022548792A (ja) | 2022-11-21 |
BR112022005349A2 (pt) | 2022-06-14 |
US11890281B2 (en) | 2024-02-06 |
TW202126660A (zh) | 2021-07-16 |
EP4034539A1 (en) | 2022-08-03 |
AU2020354475A1 (en) | 2022-05-05 |
US20210085677A1 (en) | 2021-03-25 |
WO2021061706A1 (en) | 2021-04-01 |
US20240122925A1 (en) | 2024-04-18 |
KR20220066923A (ko) | 2022-05-24 |
MX2022003454A (es) | 2022-04-19 |
CA3154862A1 (en) | 2021-04-01 |
IL291285A (en) | 2022-05-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR120082A1 (es) | Inhibidores de fosfatasa shp-2 y métodos para fabricarlos y usarlos | |
CR20210247A (es) | Nuevos compuestos heterocíclicos | |
BR112022008919A2 (pt) | Composto e método para tratamento de distúrbios psiquiátrico ou neurológico | |
UY38297A (es) | Compuestos derivados de 3-(5-hidroxi-1-oxoisoindolin-2-il)piperidina-2,6-diona, composiciones, métodos y usos de los mismos | |
MD3601283T2 (ro) | Compus inhibitor JAK pe bază de imidazo-piperidină fuzionată | |
CR20200416A (es) | Nuevos compuestos heterocíclicos | |
EA201991122A1 (ru) | 3-ЗАМЕЩЕННЫЕ ПРОПАНОВЫЕ КИСЛОТЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ИНТЕГРИНА αV | |
BR112022002375A2 (pt) | Compostos de 4,4a,5,7,8,8a-hexapirido[4,3-b][1,4]oxazin-3-ona como inibidores de magl | |
MX2021009764A (es) | Derivados de 3-(1-oxoisoindolin-2-il)piperidina-2,6-diona sustituidos y usos de los mismos. | |
MY156200A (en) | Composition for metal electroplating comprising leveling agent | |
BR112018010355A2 (pt) | método para produzir um substrato, substrato, produto, e, uso de um substrato. | |
NO20044047L (no) | Nye krystallinske former av anti-cancer forbindelsen ZD1839 | |
AR107030A1 (es) | Inhibidores aza-bencimidazol de pad4 | |
DE60235396D1 (de) | 3-amido-1,2-benzisoxazolderivate, herstellungsverfahren und deren verwendung | |
MX2018014298A (es) | Nueva forma cristalina de n-[5-(3,5-difluoro-bencilo)-1h-indazol-3 -il]-4-(4-metilo-piperazina-1-il)-2-(tetrahidro-pirano-4-ilamino) -benzamida. | |
CR20220116A (es) | Compuestos heterocíclicos | |
CR20230496A (es) | Compuestos heterocíclicos | |
CR20220004A (es) | Nuevos compuestos heterocíclicos | |
CY1115635T1 (el) | Παραγωγα 2-πυριδιν-2-υλο-πυραζολ-3(2η)-ονης, η παρασκευη τους και η εφαρμογη τους στη θεραπευτικη | |
MX2023004732A (es) | Forma cristalina iii del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. | |
MX2023004731A (es) | Forma cristalina iv del compuesto agonista de receptor de melanocortina y metodo de preparacion para la misma. | |
HRP20201402T1 (hr) | Spojevi inhibitora acetilkolinsteraze i agonisti serotonergičkih receptora 5ht4, s promnezijskim učinkom, postupci za njihovu pripremu i farmaceutski pripravci koji ih sadržavaju | |
BR112021023635A2 (pt) | Novos compostos para inibição de janus quinase 1 | |
EA202190371A1 (ru) | Композиция литейной краски для снижения выделений формальдегида | |
WO2017083086A8 (en) | HIGH VISCOSITY BASIC OIL COMPOSITIONS |